Cas 1361383-95-0,2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid

1361383-95-0

Post Buying Request

Basic information

Product Name: 2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid
Synonyms: 2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid
CAS NO:1361383-95-0
Molecular Formula:
Molecular Weight: 619.728
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: 2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid(CAS DataBase Reference)
NIST Chemistry Reference: 2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid(1361383-95-0)
EPA Substance Registry System: 2-(4-(2-(biphenyl-4-yl)-1-(4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)ethylthio)-2-methylphenoxy)acetic acid(1361383-95-0)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 1361383-95-0(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

1361383-95-0 Suppliers

Recommended suppliers

1361383-95-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1361383-95-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,3,8 and 3 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1361383-95:
(9*1)+(8*3)+(7*6)+(6*1)+(5*3)+(4*8)+(3*3)+(2*9)+(1*5)=160
160 % 10 = 0
So 1361383-95-0 is a valid CAS Registry Number.

1361383-95-0Upstream product

1361383-95-0Downstream Products

1361383-95-0Relevant academic research and scientific papers

USE OF THE FETAL REPROGRAMMING OF A PPAR AGONIST

-

, (2013/07/25)

The present invention relates to a novel use of a PPAR δ agonist, and more particularly, to a fetal reprogramming effect of a PPAR δ agonist. According to the present invention, a PPAR δ agonist adjusts calcium ion during embryo genesis and a early fetal development period to increase slow muscle fiber and to thus improve muscle endurance, thereby improving lipid and glucose metabolism and reprogramming the metabolism of the entire body, thus preventing/inhibiting the occurrence of metabolic diseases, such as obesity and diabetes in an adult body caused by a high-fat diet and a lack of exercise, and improving memory for an adult. In addition, fetal reprogramming using a PPAR δ agonist prevents/inhibits the occurrence of diabetes in a mouse model for diabetes. Therefore, the PPAR δ agonist may be used in a pharmaceutical composition for enhancing the endurance of a human and an animal by embryonic/fetal reprogramming, preventing/inhibiting metabolic diseases such as obesity, diabetes, arteriosclerosis and fatty liver, and enhancing memory. The PPAR δ agonist may also be used in a nutritional supplement for pregnant women, in food additives, in a functional food supplement or functional beverage composition, in pharmaceutical compositions for animals, in an endurance enhancer for animals, in dry milk and baby formula compositions, in an animal feed composition, etc.

Discovery, design and synthesis of Y-shaped peroxisome proliferator- activated receptor δ agonists as potent anti-obesity agents in vivo

Ham, Jungyeob,Hwang, Hoosang,Kim, Euno,Kim, Jeong-Ah,Cho, Sung Jin,Ko, Jaeyoung,Lee, Woojin,Lee, Jaehwan,Holla, Harish,Banerjee, Joydeep,Kim, Seokho,Yang, Inho,Lee, Hyun Joo,Shin, Kyoungjin,Choi, Hyukjae,Nam, Sang-Jip,Tak, Jungae,Hahn, Dongyup,Oh, Taekyung,Won, Dong Hwan,Lee, Tae Gu,Choi, Jihye,Park, Mi Sun,Seok, Chaok,Chin, Jungwook,Kang, Heonjoong

, p. 190 - 202 (2012/08/13)

We have discovered and demonstrated the in vitro and in vivo PPARδ-selective activity of novel Y-shaped agonists. These compounds activated hPPARδ with EC50 values between 1 and 523 nM. Surprisingly, compounds 10a, 11d, 11e and 11f were the mos

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 1361383-95-0